Learn how we are raising industry quality standards by using improved technology to manufacture and validate our products.
To ensure that our antibodies are specific and provide reproducible results, we have recently introduced knockout (KO) validation at scale. Using human KO cell lines, we are developing a growing range of KO-validated antibodies, including many recombinant monoclonal antibodies.
Abcam will process your personal data in strict accordance with its privacy policy which can be found here. This will include sending you updates about Abcam, our products, and resources we think would be of interest to you. You can unsubscribe and manage your marketing preferences by clicking the link at the bottom of every email we send. By filling out this form you consent to Abcam sharing your details with your local, authorized distributor for the purpose of answering your query.
Dr Alejandra Solache
Dr Alejandra Solache joined Abcam in 2013 as Head of Reagents, Product Development and Manufacturing globally. She is responsible for managing the output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically new product development, core reagents and R&D. She also plays a key role in developing our innovation strategy.
